Elaine Urbina
Concepts (456)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vascular Stiffness | 54 | 2025 | 494 | 12.560 |
Why?
| | Hypertension | 66 | 2025 | 1295 | 12.410 |
Why?
| | Blood Pressure | 73 | 2025 | 1786 | 9.660 |
Why?
| | Cardiovascular Diseases | 80 | 2025 | 2111 | 9.530 |
Why?
| | Diabetes Mellitus, Type 2 | 51 | 2025 | 2531 | 6.020 |
Why?
| | Carotid Intima-Media Thickness | 25 | 2024 | 90 | 5.810 |
Why?
| | Pulse Wave Analysis | 40 | 2025 | 272 | 5.270 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 18 | 2025 | 85 | 5.030 |
Why?
| | Adolescent | 172 | 2025 | 21513 | 3.630 |
Why?
| | Carotid Arteries | 14 | 2021 | 206 | 3.480 |
Why?
| | Blood Pressure Determination | 19 | 2025 | 157 | 3.310 |
Why?
| | Hypertrophy, Left Ventricular | 13 | 2022 | 131 | 3.280 |
Why?
| | Obesity | 38 | 2025 | 2992 | 3.260 |
Why?
| | Atherosclerosis | 15 | 2024 | 415 | 3.190 |
Why?
| | Risk Factors | 102 | 2025 | 10388 | 2.910 |
Why?
| | Pediatric Obesity | 19 | 2025 | 601 | 2.860 |
Why?
| | Diabetes Mellitus, Type 1 | 35 | 2025 | 3715 | 2.820 |
Why?
| | Child | 131 | 2025 | 21935 | 2.560 |
Why?
| | Young Adult | 93 | 2025 | 13209 | 2.380 |
Why?
| | Diabetic Angiopathies | 10 | 2025 | 259 | 2.090 |
Why?
| | Body Mass Index | 39 | 2024 | 2389 | 2.020 |
Why?
| | Risk Assessment | 24 | 2025 | 3457 | 1.880 |
Why?
| | Echocardiography | 17 | 2025 | 642 | 1.870 |
Why?
| | Dyslipidemias | 9 | 2024 | 176 | 1.850 |
Why?
| | Cross-Sectional Studies | 44 | 2025 | 5472 | 1.800 |
Why?
| | Heart Rate | 14 | 2022 | 822 | 1.780 |
Why?
| | Male | 156 | 2025 | 67762 | 1.780 |
Why?
| | Humans | 221 | 2025 | 137585 | 1.750 |
Why?
| | Female | 160 | 2025 | 73304 | 1.720 |
Why?
| | Autonomic Nervous System Diseases | 4 | 2022 | 36 | 1.680 |
Why?
| | American Heart Association | 17 | 2023 | 306 | 1.520 |
Why?
| | Heart Ventricles | 7 | 2019 | 788 | 1.410 |
Why?
| | Prevalence | 26 | 2025 | 2734 | 1.340 |
Why?
| | Ventricular Function, Left | 8 | 2022 | 534 | 1.340 |
Why?
| | Adult | 83 | 2025 | 37929 | 1.270 |
Why?
| | Carotid Artery, Common | 7 | 2021 | 36 | 1.250 |
Why?
| | Obesity, Morbid | 6 | 2020 | 264 | 1.230 |
Why?
| | United States | 55 | 2024 | 14841 | 1.220 |
Why?
| | Brachial Artery | 10 | 2024 | 205 | 1.210 |
Why?
| | Lipoproteins | 6 | 2023 | 168 | 1.210 |
Why?
| | Masked Hypertension | 3 | 2025 | 4 | 1.170 |
Why?
| | Practice Guidelines as Topic | 12 | 2021 | 1587 | 1.110 |
Why?
| | Cholesterol, LDL | 14 | 2024 | 365 | 1.090 |
Why?
| | Adiposity | 5 | 2021 | 518 | 1.060 |
Why?
| | Ventricular Dysfunction, Left | 5 | 2021 | 382 | 1.060 |
Why?
| | Cholesterol | 11 | 2024 | 410 | 1.050 |
Why?
| | White Coat Hypertension | 3 | 2025 | 7 | 1.040 |
Why?
| | Blood Glucose | 9 | 2020 | 2186 | 1.030 |
Why?
| | Triglycerides | 12 | 2024 | 524 | 0.980 |
Why?
| | Age Factors | 20 | 2020 | 3295 | 0.970 |
Why?
| | Sodium, Dietary | 2 | 2023 | 41 | 0.940 |
Why?
| | Metabolic Syndrome | 7 | 2019 | 354 | 0.940 |
Why?
| | Cholesterol, HDL | 8 | 2024 | 203 | 0.910 |
Why?
| | Lipids | 8 | 2024 | 672 | 0.900 |
Why?
| | Wearable Electronic Devices | 1 | 2025 | 53 | 0.890 |
Why?
| | Arteries | 4 | 2023 | 269 | 0.830 |
Why?
| | Tunica Intima | 8 | 2011 | 84 | 0.830 |
Why?
| | Carotid Artery Diseases | 5 | 2017 | 64 | 0.820 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2025 | 184 | 0.800 |
Why?
| | Pediatrics | 3 | 2021 | 1101 | 0.790 |
Why?
| | Diabetic Neuropathies | 4 | 2023 | 94 | 0.790 |
Why?
| | Asymptomatic Diseases | 3 | 2020 | 89 | 0.780 |
Why?
| | September 11 Terrorist Attacks | 3 | 2017 | 32 | 0.780 |
Why?
| | Longitudinal Studies | 19 | 2025 | 2844 | 0.770 |
Why?
| | Prehypertension | 2 | 2013 | 28 | 0.760 |
Why?
| | Tunica Media | 3 | 2011 | 38 | 0.750 |
Why?
| | Academies and Institutes | 2 | 2021 | 53 | 0.750 |
Why?
| | Atrial Fibrillation | 3 | 2023 | 388 | 0.740 |
Why?
| | Systole | 9 | 2024 | 189 | 0.740 |
Why?
| | Vascular Resistance | 7 | 2014 | 375 | 0.730 |
Why?
| | Autonomic Nervous System | 4 | 2019 | 75 | 0.720 |
Why?
| | Muscular Dystrophy, Duchenne | 3 | 2021 | 89 | 0.720 |
Why?
| | Biomedical Research | 4 | 2019 | 692 | 0.710 |
Why?
| | Cardiomyopathies | 2 | 2022 | 350 | 0.700 |
Why?
| | Mass Screening | 5 | 2019 | 1287 | 0.700 |
Why?
| | Vasodilation | 4 | 2017 | 499 | 0.700 |
Why?
| | Follow-Up Studies | 16 | 2021 | 5131 | 0.700 |
Why?
| | Adolescent Health | 1 | 2021 | 39 | 0.690 |
Why?
| | Ohio | 9 | 2016 | 152 | 0.690 |
Why?
| | Essential Hypertension | 2 | 2023 | 5 | 0.680 |
Why?
| | Endothelium, Vascular | 7 | 2018 | 927 | 0.660 |
Why?
| | Exercise | 5 | 2019 | 2057 | 0.660 |
Why?
| | Diet, Mediterranean | 1 | 2020 | 30 | 0.660 |
Why?
| | Arteriosclerosis | 3 | 2013 | 88 | 0.650 |
Why?
| | Nervous System Diseases | 1 | 2023 | 266 | 0.650 |
Why?
| | Insulin Resistance | 6 | 2022 | 1208 | 0.650 |
Why?
| | Preventive Medicine | 1 | 2020 | 42 | 0.640 |
Why?
| | Life Style | 4 | 2021 | 490 | 0.590 |
Why?
| | Arrhythmias, Cardiac | 2 | 2022 | 333 | 0.560 |
Why?
| | Program Development | 1 | 2020 | 364 | 0.560 |
Why?
| | Predictive Value of Tests | 10 | 2024 | 2031 | 0.550 |
Why?
| | Environmental Exposure | 5 | 2021 | 579 | 0.540 |
Why?
| | Cardiology | 1 | 2020 | 274 | 0.540 |
Why?
| | Case-Control Studies | 12 | 2021 | 3556 | 0.540 |
Why?
| | Sex Factors | 14 | 2019 | 2071 | 0.540 |
Why?
| | Accelerometry | 1 | 2017 | 103 | 0.520 |
Why?
| | Elasticity | 4 | 2011 | 197 | 0.500 |
Why?
| | Prospective Studies | 18 | 2024 | 7604 | 0.500 |
Why?
| | Advisory Committees | 2 | 2016 | 219 | 0.490 |
Why?
| | Particle Size | 1 | 2017 | 394 | 0.490 |
Why?
| | Environmental Pollutants | 2 | 2019 | 159 | 0.480 |
Why?
| | Self Report | 2 | 2020 | 827 | 0.480 |
Why?
| | Blood Pressure Monitors | 1 | 2015 | 3 | 0.480 |
Why?
| | Prediabetic State | 2 | 2016 | 253 | 0.480 |
Why?
| | Incidence | 13 | 2024 | 2804 | 0.470 |
Why?
| | Anticholesteremic Agents | 3 | 2014 | 153 | 0.470 |
Why?
| | Linear Models | 9 | 2021 | 849 | 0.470 |
Why?
| | Overweight | 6 | 2024 | 558 | 0.460 |
Why?
| | Cohort Studies | 19 | 2024 | 5742 | 0.460 |
Why?
| | Child, Preschool | 25 | 2025 | 11074 | 0.450 |
Why?
| | DNA Methylation | 2 | 2019 | 643 | 0.450 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2017 | 177 | 0.440 |
Why?
| | Disease Management | 2 | 2019 | 628 | 0.440 |
Why?
| | Epigenesis, Genetic | 1 | 2019 | 660 | 0.430 |
Why?
| | Health Planning Guidelines | 1 | 2013 | 25 | 0.430 |
Why?
| | Multivariate Analysis | 6 | 2021 | 1509 | 0.430 |
Why?
| | Vasculitis | 1 | 2014 | 66 | 0.430 |
Why?
| | Vascular Remodeling | 1 | 2015 | 193 | 0.420 |
Why?
| | Peripheral Vascular Diseases | 1 | 2014 | 103 | 0.420 |
Why?
| | Blood Vessels | 2 | 2025 | 187 | 0.420 |
Why?
| | Heart Diseases | 3 | 2022 | 346 | 0.420 |
Why?
| | Microvessels | 1 | 2014 | 88 | 0.410 |
Why?
| | Aorta | 3 | 2025 | 417 | 0.410 |
Why?
| | Vascular Diseases | 4 | 2020 | 243 | 0.410 |
Why?
| | Fibrosis | 2 | 2021 | 552 | 0.410 |
Why?
| | Observational Studies as Topic | 1 | 2013 | 117 | 0.410 |
Why?
| | Diastole | 7 | 2022 | 149 | 0.400 |
Why?
| | Hyperlipoproteinemia Type II | 4 | 2021 | 35 | 0.400 |
Why?
| | Phthalic Acids | 1 | 2013 | 40 | 0.400 |
Why?
| | Prognosis | 8 | 2021 | 4030 | 0.390 |
Why?
| | Aging | 4 | 2025 | 1864 | 0.380 |
Why?
| | Stroke Volume | 4 | 2022 | 612 | 0.350 |
Why?
| | Tuberculosis | 2 | 2024 | 279 | 0.350 |
Why?
| | Carotid Artery, Internal | 1 | 2011 | 42 | 0.350 |
Why?
| | Myocardium | 2 | 2021 | 1002 | 0.340 |
Why?
| | Body Weight | 6 | 2021 | 985 | 0.340 |
Why?
| | Patient Compliance | 3 | 2024 | 581 | 0.330 |
Why?
| | Air Pollutants | 3 | 2021 | 430 | 0.330 |
Why?
| | HIV Infections | 2 | 2025 | 2836 | 0.330 |
Why?
| | Biomarkers | 15 | 2025 | 4149 | 0.330 |
Why?
| | Finland | 7 | 2024 | 85 | 0.320 |
Why?
| | Inflammation | 5 | 2021 | 2837 | 0.320 |
Why?
| | Adiponectin | 1 | 2012 | 244 | 0.320 |
Why?
| | Blood Flow Velocity | 5 | 2014 | 413 | 0.320 |
Why?
| | Disease Progression | 7 | 2021 | 2757 | 0.310 |
Why?
| | Bariatric Surgery | 3 | 2018 | 217 | 0.310 |
Why?
| | Exercise Tolerance | 2 | 2022 | 279 | 0.310 |
Why?
| | Early Diagnosis | 2 | 2024 | 242 | 0.300 |
Why?
| | Heart Failure | 2 | 2022 | 2236 | 0.300 |
Why?
| | Carotid Stenosis | 1 | 2009 | 91 | 0.290 |
Why?
| | Pulsatile Flow | 4 | 2014 | 60 | 0.290 |
Why?
| | Albuminuria | 2 | 2025 | 185 | 0.280 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2013 | 1477 | 0.280 |
Why?
| | Heart | 2 | 2023 | 655 | 0.270 |
Why?
| | Sulfonamides | 2 | 2022 | 513 | 0.270 |
Why?
| | Turner Syndrome | 2 | 2020 | 54 | 0.270 |
Why?
| | Air Pollution | 3 | 2021 | 316 | 0.270 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2009 | 267 | 0.270 |
Why?
| | Ultrasonography | 8 | 2021 | 759 | 0.270 |
Why?
| | Lipoproteins, HDL | 3 | 2021 | 77 | 0.270 |
Why?
| | Bone Density | 2 | 2021 | 489 | 0.260 |
Why?
| | Executive Function | 2 | 2024 | 451 | 0.260 |
Why?
| | Diagnostic Imaging | 1 | 2009 | 332 | 0.260 |
Why?
| | Fluorocarbons | 2 | 2019 | 117 | 0.260 |
Why?
| | Coronary Artery Disease | 3 | 2019 | 698 | 0.250 |
Why?
| | Health Promotion | 3 | 2019 | 741 | 0.250 |
Why?
| | Australia | 6 | 2024 | 315 | 0.250 |
Why?
| | Time Factors | 6 | 2020 | 6828 | 0.250 |
Why?
| | Aortic Diseases | 2 | 2017 | 119 | 0.240 |
Why?
| | Comorbidity | 4 | 2019 | 1622 | 0.230 |
Why?
| | Age Distribution | 4 | 2021 | 392 | 0.230 |
Why?
| | Renin-Angiotensin System | 1 | 2025 | 85 | 0.220 |
Why?
| | Anthropometry | 3 | 2019 | 213 | 0.220 |
Why?
| | Lipoprotein(a) | 2 | 2022 | 67 | 0.220 |
Why?
| | Age of Onset | 4 | 2021 | 518 | 0.220 |
Why?
| | Consensus | 3 | 2025 | 683 | 0.220 |
Why?
| | Diabetes Mellitus | 3 | 2018 | 1040 | 0.210 |
Why?
| | Middle Aged | 17 | 2025 | 33479 | 0.210 |
Why?
| | Smoking | 4 | 2024 | 1627 | 0.210 |
Why?
| | Latent Tuberculosis | 1 | 2024 | 69 | 0.200 |
Why?
| | Femoral Artery | 3 | 2014 | 179 | 0.200 |
Why?
| | Vehicle Emissions | 2 | 2021 | 67 | 0.200 |
Why?
| | Antihypertensive Agents | 3 | 2024 | 494 | 0.200 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 2 | 2021 | 104 | 0.190 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3566 | 0.190 |
Why?
| | Research Design | 2 | 2019 | 1139 | 0.190 |
Why?
| | Hypoglycemic Agents | 3 | 2020 | 1291 | 0.190 |
Why?
| | Data Collection | 1 | 2025 | 673 | 0.190 |
Why?
| | Heart Arrest, Induced | 1 | 2002 | 31 | 0.190 |
Why?
| | Waist Circumference | 2 | 2019 | 143 | 0.190 |
Why?
| | Fontan Procedure | 2 | 2021 | 180 | 0.180 |
Why?
| | Pilot Projects | 4 | 2022 | 1710 | 0.180 |
Why?
| | Albumins | 1 | 2022 | 114 | 0.180 |
Why?
| | Transposition of Great Vessels | 1 | 2002 | 36 | 0.180 |
Why?
| | Sphygmomanometers | 3 | 2012 | 9 | 0.180 |
Why?
| | Acute-Phase Proteins | 1 | 2021 | 67 | 0.180 |
Why?
| | Triage | 1 | 2024 | 222 | 0.180 |
Why?
| | Ventricular Remodeling | 2 | 2021 | 266 | 0.180 |
Why?
| | Women's Health | 3 | 2011 | 372 | 0.180 |
Why?
| | Feasibility Studies | 1 | 2025 | 956 | 0.180 |
Why?
| | Reference Values | 5 | 2025 | 816 | 0.180 |
Why?
| | Allostasis | 1 | 2021 | 17 | 0.180 |
Why?
| | Insulin | 3 | 2020 | 2409 | 0.180 |
Why?
| | Interdisciplinary Research | 1 | 2021 | 27 | 0.180 |
Why?
| | Attention | 1 | 2024 | 427 | 0.180 |
Why?
| | Myocarditis | 1 | 2022 | 100 | 0.170 |
Why?
| | Atrial Function, Left | 1 | 2020 | 7 | 0.170 |
Why?
| | Sodium | 1 | 2022 | 217 | 0.170 |
Why?
| | Birth Weight | 1 | 2024 | 516 | 0.170 |
Why?
| | Parity | 1 | 2021 | 126 | 0.170 |
Why?
| | Quantitative Trait, Heritable | 1 | 2021 | 125 | 0.170 |
Why?
| | Forecasting | 2 | 2020 | 389 | 0.170 |
Why?
| | Sex Distribution | 2 | 2021 | 375 | 0.170 |
Why?
| | Sensitivity and Specificity | 2 | 2024 | 1946 | 0.170 |
Why?
| | Creatinine | 1 | 2022 | 499 | 0.170 |
Why?
| | Epoprostenol | 1 | 2021 | 136 | 0.160 |
Why?
| | Precision Medicine | 1 | 2024 | 429 | 0.160 |
Why?
| | Paternal Exposure | 1 | 2019 | 2 | 0.160 |
Why?
| | Pyrimidines | 2 | 2022 | 470 | 0.160 |
Why?
| | Absorptiometry, Photon | 3 | 2021 | 259 | 0.160 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2019 | 37 | 0.160 |
Why?
| | Motivation | 1 | 2024 | 570 | 0.160 |
Why?
| | Regional Blood Flow | 2 | 2014 | 474 | 0.160 |
Why?
| | Diabetes Complications | 4 | 2023 | 227 | 0.160 |
Why?
| | Cognition | 2 | 2024 | 1153 | 0.160 |
Why?
| | National Institute of Child Health and Human Development (U.S.) | 1 | 2019 | 9 | 0.160 |
Why?
| | Retrospective Studies | 11 | 2025 | 15657 | 0.160 |
Why?
| | Colorado | 5 | 2015 | 4565 | 0.160 |
Why?
| | Preconception Care | 1 | 2019 | 43 | 0.150 |
Why?
| | Cell Adhesion Molecules | 1 | 2020 | 181 | 0.150 |
Why?
| | Smokers | 1 | 2020 | 145 | 0.150 |
Why?
| | Sugars | 1 | 2019 | 41 | 0.150 |
Why?
| | Histone Code | 1 | 2019 | 34 | 0.150 |
Why?
| | Dimensional Measurement Accuracy | 1 | 2018 | 13 | 0.150 |
Why?
| | Judaism | 1 | 2018 | 3 | 0.150 |
Why?
| | Compression Bandages | 1 | 2018 | 5 | 0.150 |
Why?
| | Fasting | 1 | 2020 | 281 | 0.150 |
Why?
| | Dietary Carbohydrates | 1 | 2019 | 155 | 0.150 |
Why?
| | Ischemic Preconditioning | 1 | 2018 | 41 | 0.140 |
Why?
| | Preventive Health Services | 2 | 2017 | 148 | 0.140 |
Why?
| | Nutrition Surveys | 2 | 2024 | 266 | 0.140 |
Why?
| | Maternal Exposure | 1 | 2019 | 190 | 0.140 |
Why?
| | Infant, Newborn | 5 | 2025 | 6079 | 0.140 |
Why?
| | ROC Curve | 1 | 2019 | 554 | 0.140 |
Why?
| | Bone and Bones | 1 | 2020 | 317 | 0.140 |
Why?
| | Cognitive Dysfunction | 2 | 2023 | 383 | 0.140 |
Why?
| | Infant | 7 | 2025 | 9465 | 0.140 |
Why?
| | Guidelines as Topic | 1 | 2019 | 275 | 0.130 |
Why?
| | Diethylhexyl Phthalate | 1 | 2017 | 15 | 0.130 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2021 | 293 | 0.130 |
Why?
| | Proprotein Convertase 9 | 1 | 2017 | 73 | 0.130 |
Why?
| | Genetic Predisposition to Disease | 3 | 2021 | 2426 | 0.130 |
Why?
| | Hypolipidemic Agents | 2 | 2007 | 91 | 0.130 |
Why?
| | Myocardial Infarction | 1 | 2024 | 1046 | 0.130 |
Why?
| | Morbidity | 2 | 2014 | 324 | 0.130 |
Why?
| | Phenotype | 1 | 2025 | 3196 | 0.130 |
Why?
| | Benzhydryl Compounds | 1 | 2017 | 73 | 0.130 |
Why?
| | Risk | 1 | 2019 | 912 | 0.130 |
Why?
| | Body Size | 1 | 2017 | 108 | 0.130 |
Why?
| | Cardiac Surgical Procedures | 1 | 2002 | 530 | 0.120 |
Why?
| | Phenols | 1 | 2017 | 99 | 0.120 |
Why?
| | Cytokines | 2 | 2021 | 2085 | 0.120 |
Why?
| | School Health Services | 1 | 2019 | 238 | 0.120 |
Why?
| | Population Surveillance | 1 | 2019 | 482 | 0.120 |
Why?
| | Smoking Cessation | 1 | 2020 | 442 | 0.120 |
Why?
| | Adolescent Behavior | 3 | 2020 | 530 | 0.120 |
Why?
| | Memory, Short-Term | 1 | 2018 | 250 | 0.120 |
Why?
| | Schools | 1 | 2019 | 461 | 0.120 |
Why?
| | MicroRNAs | 2 | 2019 | 692 | 0.120 |
Why?
| | Diet Therapy | 1 | 2015 | 37 | 0.120 |
Why?
| | Ankle Brachial Index | 1 | 2015 | 37 | 0.120 |
Why?
| | Chemical Industry | 1 | 2014 | 12 | 0.120 |
Why?
| | Petroleum | 1 | 2014 | 10 | 0.110 |
Why?
| | Referral and Consultation | 1 | 2020 | 786 | 0.110 |
Why?
| | Sleep Wake Disorders | 1 | 2018 | 286 | 0.110 |
Why?
| | Polycyclic Aromatic Hydrocarbons | 1 | 2014 | 29 | 0.110 |
Why?
| | Health Behavior | 2 | 2020 | 762 | 0.110 |
Why?
| | Arm | 2 | 2018 | 104 | 0.110 |
Why?
| | Tachycardia | 1 | 2014 | 57 | 0.110 |
Why?
| | Cardiac Output | 1 | 2015 | 165 | 0.110 |
Why?
| | Chi-Square Distribution | 1 | 2015 | 530 | 0.110 |
Why?
| | Electrocardiography, Ambulatory | 1 | 2014 | 63 | 0.110 |
Why?
| | Laser-Doppler Flowmetry | 1 | 2014 | 32 | 0.110 |
Why?
| | Forearm | 1 | 2014 | 119 | 0.110 |
Why?
| | Diabetic Cardiomyopathies | 1 | 2014 | 36 | 0.110 |
Why?
| | Dietary Fiber | 1 | 2014 | 54 | 0.110 |
Why?
| | Oxidative Stress | 2 | 2018 | 1317 | 0.100 |
Why?
| | Diet | 1 | 2021 | 1278 | 0.100 |
Why?
| | Heart Defects, Congenital | 1 | 2021 | 842 | 0.100 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2016 | 611 | 0.100 |
Why?
| | Surveys and Questionnaires | 3 | 2017 | 5778 | 0.100 |
Why?
| | Vitamin D Deficiency | 1 | 2015 | 186 | 0.100 |
Why?
| | Hyperglycemia | 2 | 2014 | 347 | 0.100 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2019 | 605 | 0.100 |
Why?
| | Regression Analysis | 2 | 2014 | 1024 | 0.100 |
Why?
| | Oscillometry | 2 | 2011 | 42 | 0.100 |
Why?
| | Exercise Therapy | 2 | 2015 | 443 | 0.100 |
Why?
| | Logistic Models | 2 | 2017 | 2074 | 0.090 |
Why?
| | Mercury | 1 | 2012 | 41 | 0.090 |
Why?
| | Research | 1 | 2015 | 451 | 0.090 |
Why?
| | Vitamin D | 1 | 2015 | 397 | 0.090 |
Why?
| | Aortic Coarctation | 1 | 2012 | 83 | 0.090 |
Why?
| | Hot Temperature | 1 | 2014 | 391 | 0.090 |
Why?
| | Louisiana | 4 | 2004 | 29 | 0.090 |
Why?
| | Hemodynamics | 2 | 2018 | 1113 | 0.090 |
Why?
| | Rhinitis | 1 | 2012 | 158 | 0.090 |
Why?
| | Aged | 3 | 2025 | 23961 | 0.080 |
Why?
| | Environmental Monitoring | 1 | 2013 | 370 | 0.080 |
Why?
| | Pregnancy | 5 | 2024 | 6763 | 0.080 |
Why?
| | Gastroesophageal Reflux | 1 | 2012 | 234 | 0.080 |
Why?
| | Child Welfare | 1 | 2012 | 216 | 0.080 |
Why?
| | Uric Acid | 2 | 2024 | 163 | 0.080 |
Why?
| | Postoperative Complications | 2 | 2021 | 2654 | 0.080 |
Why?
| | Allylamine | 1 | 2009 | 8 | 0.080 |
Why?
| | Skin | 1 | 2014 | 752 | 0.080 |
Why?
| | Motor Activity | 2 | 2014 | 718 | 0.080 |
Why?
| | Exercise Test | 1 | 2012 | 625 | 0.080 |
Why?
| | Cluster Analysis | 1 | 2011 | 499 | 0.080 |
Why?
| | Manometry | 1 | 2009 | 95 | 0.080 |
Why?
| | Reproducibility of Results | 3 | 2024 | 3284 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2828 | 0.080 |
Why?
| | Ultrasonography, Doppler | 1 | 2009 | 124 | 0.080 |
Why?
| | Leg | 1 | 2010 | 236 | 0.070 |
Why?
| | Statistics as Topic | 3 | 2004 | 307 | 0.070 |
Why?
| | Eating | 2 | 2021 | 380 | 0.070 |
Why?
| | Particulate Matter | 2 | 2021 | 315 | 0.070 |
Why?
| | Combined Modality Therapy | 3 | 2020 | 1236 | 0.070 |
Why?
| | Magnetic Resonance Angiography | 1 | 2009 | 240 | 0.070 |
Why?
| | Health Surveys | 2 | 2020 | 514 | 0.070 |
Why?
| | Neoplasms | 1 | 2021 | 2671 | 0.060 |
Why?
| | C-Reactive Protein | 2 | 2019 | 410 | 0.060 |
Why?
| | Fibrinogen | 2 | 2019 | 168 | 0.060 |
Why?
| | Weight Loss | 2 | 2024 | 787 | 0.060 |
Why?
| | Metformin | 2 | 2020 | 331 | 0.060 |
Why?
| | Midwestern United States | 1 | 2024 | 45 | 0.060 |
Why?
| | Arterial Occlusive Diseases | 1 | 2004 | 83 | 0.050 |
Why?
| | Treatment Outcome | 4 | 2019 | 10811 | 0.050 |
Why?
| | Bioprosthesis | 1 | 2003 | 40 | 0.050 |
Why?
| | Nitric Oxide Synthase | 1 | 2004 | 240 | 0.050 |
Why?
| | Adipose Tissue | 1 | 2008 | 635 | 0.050 |
Why?
| | Ventricular Outflow Obstruction | 1 | 2003 | 43 | 0.050 |
Why?
| | Mass Spectrometry | 2 | 2019 | 739 | 0.050 |
Why?
| | Drug Therapy, Combination | 2 | 2020 | 1066 | 0.050 |
Why?
| | Arterial Pressure | 1 | 2023 | 126 | 0.050 |
Why?
| | Heart Valve Prosthesis | 1 | 2003 | 114 | 0.050 |
Why?
| | Body Constitution | 1 | 2002 | 55 | 0.050 |
Why?
| | Reward | 1 | 2024 | 244 | 0.050 |
Why?
| | Iowa | 1 | 2021 | 30 | 0.050 |
Why?
| | Heart Atria | 1 | 2022 | 137 | 0.050 |
Why?
| | Ventricular Function | 1 | 2002 | 61 | 0.050 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2008 | 617 | 0.050 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2003 | 180 | 0.040 |
Why?
| | Mendelian Randomization Analysis | 1 | 2021 | 50 | 0.040 |
Why?
| | Venous Pressure | 1 | 2021 | 8 | 0.040 |
Why?
| | Gadolinium | 1 | 2021 | 82 | 0.040 |
Why?
| | Polymorphism, Genetic | 1 | 2004 | 660 | 0.040 |
Why?
| | Intra-Abdominal Fat | 1 | 2021 | 91 | 0.040 |
Why?
| | Sitosterols | 1 | 2020 | 2 | 0.040 |
Why?
| | Pregnancy Complications | 2 | 2019 | 527 | 0.040 |
Why?
| | Stem Cell Transplantation | 1 | 2022 | 176 | 0.040 |
Why?
| | Phytosterols | 1 | 2020 | 12 | 0.040 |
Why?
| | Double-Blind Method | 2 | 2019 | 1993 | 0.040 |
Why?
| | Body Height | 1 | 2021 | 199 | 0.040 |
Why?
| | United Kingdom | 1 | 2021 | 318 | 0.040 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2021 | 193 | 0.040 |
Why?
| | Myocardial Contraction | 1 | 2002 | 341 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2021 | 310 | 0.040 |
Why?
| | Placebo Effect | 1 | 2019 | 25 | 0.040 |
Why?
| | Echocardiography, Doppler | 1 | 2020 | 108 | 0.040 |
Why?
| | Infant Health | 1 | 2019 | 25 | 0.040 |
Why?
| | Croatia | 1 | 2019 | 5 | 0.040 |
Why?
| | Organ Size | 1 | 2020 | 477 | 0.040 |
Why?
| | Public Health | 1 | 2024 | 588 | 0.040 |
Why?
| | Intersectoral Collaboration | 1 | 2019 | 60 | 0.040 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2019 | 99 | 0.040 |
Why?
| | Infertility | 1 | 2019 | 55 | 0.040 |
Why?
| | Electrocardiography | 1 | 2022 | 629 | 0.040 |
Why?
| | Research Support as Topic | 1 | 2019 | 119 | 0.040 |
Why?
| | Education | 1 | 2019 | 108 | 0.040 |
Why?
| | Risk Reduction Behavior | 1 | 2020 | 220 | 0.040 |
Why?
| | Contrast Media | 1 | 2021 | 467 | 0.040 |
Why?
| | Athletes | 1 | 2022 | 423 | 0.040 |
Why?
| | Alabama | 1 | 2018 | 33 | 0.040 |
Why?
| | Diabetic Retinopathy | 1 | 2020 | 189 | 0.040 |
Why?
| | Carbon | 1 | 2019 | 216 | 0.040 |
Why?
| | Child Health | 1 | 2019 | 154 | 0.040 |
Why?
| | Child Behavior | 1 | 2020 | 248 | 0.030 |
Why?
| | New York City | 1 | 2017 | 85 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 786 | 0.030 |
Why?
| | Transition to Adult Care | 1 | 2019 | 91 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2019 | 233 | 0.030 |
Why?
| | Oxygen | 1 | 2022 | 931 | 0.030 |
Why?
| | Guideline Adherence | 2 | 2012 | 556 | 0.030 |
Why?
| | Radial Artery | 1 | 2017 | 68 | 0.030 |
Why?
| | Diabetic Nephropathies | 1 | 2020 | 294 | 0.030 |
Why?
| | Body Surface Area | 1 | 2016 | 34 | 0.030 |
Why?
| | Animals | 1 | 2019 | 36940 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2016 | 62 | 0.030 |
Why?
| | Oxygen Consumption | 1 | 2019 | 696 | 0.030 |
Why?
| | Europe | 1 | 2017 | 414 | 0.030 |
Why?
| | Patient Education as Topic | 2 | 2011 | 766 | 0.030 |
Why?
| | Terminology as Topic | 1 | 2017 | 216 | 0.030 |
Why?
| | Thrombosis | 1 | 2019 | 371 | 0.030 |
Why?
| | Fractures, Bone | 1 | 2020 | 380 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2019 | 778 | 0.030 |
Why?
| | Videoconferencing | 1 | 2015 | 66 | 0.030 |
Why?
| | Patient Selection | 1 | 2018 | 696 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1266 | 0.030 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2009 | 445 | 0.030 |
Why?
| | Nutrition Policy | 1 | 2014 | 61 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2018 | 1289 | 0.030 |
Why?
| | Blood Cell Count | 1 | 2012 | 55 | 0.020 |
Why?
| | Internationality | 1 | 2013 | 155 | 0.020 |
Why?
| | Dust | 1 | 2012 | 100 | 0.020 |
Why?
| | Databases, Factual | 1 | 2018 | 1357 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2015 | 1316 | 0.020 |
Why?
| | Liver | 1 | 2021 | 1943 | 0.020 |
Why?
| | Clinical Trials as Topic | 2 | 2007 | 1050 | 0.020 |
Why?
| | Spirometry | 1 | 2012 | 281 | 0.020 |
Why?
| | Headache | 1 | 2012 | 147 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2017 | 762 | 0.020 |
Why?
| | Inservice Training | 1 | 2012 | 116 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1774 | 0.020 |
Why?
| | Chronic Disease | 1 | 2017 | 1793 | 0.020 |
Why?
| | Observer Variation | 1 | 2012 | 343 | 0.020 |
Why?
| | Health Status | 1 | 2016 | 792 | 0.020 |
Why?
| | Sound | 1 | 2011 | 48 | 0.020 |
Why?
| | Eosinophils | 1 | 2012 | 332 | 0.020 |
Why?
| | Colesevelam Hydrochloride | 1 | 2009 | 8 | 0.020 |
Why?
| | Circadian Rhythm | 1 | 2014 | 468 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2017 | 1069 | 0.020 |
Why?
| | Registries | 1 | 2017 | 2035 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2021 | 7635 | 0.020 |
Why?
| | Social Class | 1 | 2011 | 282 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2011 | 591 | 0.020 |
Why?
| | Hyperlipoproteinemias | 1 | 2007 | 6 | 0.020 |
Why?
| | Cholesterol, Dietary | 1 | 2007 | 18 | 0.020 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2009 | 250 | 0.020 |
Why?
| | Contraindications | 1 | 2007 | 90 | 0.020 |
Why?
| | Diet, Fat-Restricted | 1 | 2007 | 79 | 0.020 |
Why?
| | HIV Protease Inhibitors | 1 | 2007 | 69 | 0.020 |
Why?
| | Phytotherapy | 1 | 2007 | 83 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2009 | 2057 | 0.010 |
Why?
| | Dietary Fats | 1 | 2007 | 304 | 0.010 |
Why?
| | Equipment Design | 1 | 2006 | 522 | 0.010 |
Why?
| | Glomerular Filtration Rate | 1 | 2008 | 746 | 0.010 |
Why?
| | Los Angeles | 1 | 2003 | 76 | 0.010 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2004 | 204 | 0.010 |
Why?
| | Genetic Markers | 1 | 2004 | 344 | 0.010 |
Why?
| | Gene Frequency | 1 | 2004 | 521 | 0.010 |
Why?
| | Pulmonary Valve | 1 | 2003 | 97 | 0.010 |
Why?
| | Alleles | 1 | 2004 | 891 | 0.010 |
Why?
| | Aortic Valve | 1 | 2003 | 351 | 0.010 |
Why?
| | Asthma | 1 | 2012 | 2295 | 0.010 |
Why?
| | Genotype | 1 | 2004 | 1916 | 0.010 |
Why?
| | Pulmonary Artery | 1 | 2003 | 1086 | 0.010 |
Why?
|
|
Urbina's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|